Abstract
Background/Aims
Disorders of Sex Development (DSD) are congenital conditions in which chromosomal, gonadal, or anatomic sex development is atypical. Optimal management is patient- and family-centered and delivered by interdisciplinary teams. The present pilot study elicits concerns held by important stakeholders on issues affecting young patients with DSD and their families.
Methods
Content from focus groups with expert clinicians (pediatric urologists [n=7], pediatric endocrinologists [n=10], mental health professionals [n=4]), DSD patient advocates (n=4), and interviews with parents of DSD-affected children (newborn to 6 yrs; n=11) was coded and content-analyzed to identify health-related quality of life issues.
Results
Key stressors varied across stakeholder groups. In general, family-centered issues were noted more than child-centered. In the child-centered domain, providers worried more about physical functioning; family and advocates emphasized gender concerns and body image. In the family-centered domain, parental concerns about medication management outweighed those of providers. Advocates reported more stressors regarding communication/information than other stakeholders.
Conclusion
Variability exists across stakeholder groups in the key concerns affecting young children/families with DSD. Interdisciplinary DSD healthcare team development should account for varying perspectives when counseling families and planning treatment.
Disorders of Sex Development (DSD) are defined as congenital conditions in which development of chromosomal, gonadal, or anatomic sex is atypical 4. Medical and surgical recommendation for managing DSD has shifted over the past 50 years, in part because of a greater understanding of the process of psychosexual differentiation. At this juncture, a consensus statement has been issued by the Lawson Wilkins Pediatric Endocrine Society (renamed the Pediatric Endocrine Society in 2010) and the European Society for Paediatric Endocrinology, that calls for patient- and family-centered care delivered by an integrated, interdisciplinary team 4.
This optimal type of care requires that the differing perspectives of stakeholder groups (e.g., parents, health care providers) be understood. To date, only limited data examining the perspectives of parents of children with DSD exist 5,6, and studies of DSD healthcare provider beliefs have, until now, not been conducted. Given this shift in care practices, systematic assessment of patient outcomes is necessary to evaluate whether these changes in care have produced positive effects. The purpose of this study was to identify key concerns affecting young children with DSD and their parents through in-depth, qualitative interviews with health care providers caring for patients with DSD (e.g., urologists, endocrinologists, mental health professionals), parents of young children with DSD, and advocates for this population.
The identification of key issues represents the first step in developing outcome measures that reflect how DSD affect the health-related quality of life (HRQoL) of patients and families. HRQoL is a multidimensional construct comprising several core dimensions (e.g., physical functioning and symptoms, psychological and emotional state, and social functioning); is patient/family, rather than physician-centered; and reflects subjective evaluations of daily functioning and psychological well-being 7,8. HRQoL measures are now frequently included in clinical trials 9, and are recommended as a key patient-reported outcomes (PROs) for chronic conditions 10. In recent years, a consensus has emerged that disease/category-specific measures are more sensitive to “smaller differences and smaller changes over time than generic measures 11. Careful assessment of HRQoL measures in a variety of chronic diseases, such as cystic fibrosis, asthma, epilepsy, and cancer have all shown that disease/category-specific measures provide more precise measurement, more power to detect differences, and are more likely to lead to effective interventions 2,3,8,12,13. There is an acute need for measures that describe how DSD affects the daily functioning of children and families, track the efficacy of new interventions or models of care, and identify strategies to improve care.
The present study elucidates, compares, and contrasts the concerns held by important stakeholders regarding salient issues affecting patients with DSD and their families. In contrast to more quantitative methods, a qualitative approach 14, making use of interviews and focus groups with these stakeholders, was used to elicit critical stressors and concerns about DSD management that would provide the foundation for developing a HRQoL instrument.
Methods
As a first step in the development of a HRQoL measure for children with DSD and their parents, we conducted a series of focus groups and interviews to identify the key issues for children and families with DSD. U.S. and Canadian healthcare providers were selected to participate in telephone-based focus groups if they had substantial experience in the management of DSD, as evidenced by peer-reviewed publications on DSD, discipline-specific DSD committee work, and/or leadership responsibilities in their respective professional societies. Informed consent documents were mailed to 21 pediatric urologists, 22 pediatric endocrinologists, and 10 mental health providers; return rates were 48%, 59%, and 60%, respectively. There were no refusals and there were no discernable differences in professional experience or leadership responsibilities between those who returned informed consent vs. those who did not.
Due to scheduling conflicts, the numbers participating in the focus groups were as follows: 7 pediatric urologists, 10 pediatric endocrinologists and 4 mental health providers (2 pediatric psychologists, 1 social worker, and 1 psychiatrist). DSD patient advocates (n=4; 1 of whom is affected), were recruited for telephone-based focus groups from the leadership of U.S. national advocacy/parent support organizations. This stakeholder group included a leader of a national not-for-profit condition-specific organization; a parent of a DSD-affected child who organizes peer support events under the auspices of a second national not-for-profit organization for parents of children with chronic medical conditions; and two executive directors of DSD advocacy organizations. Finally, parents of young (newborn to 6 yrs) DSD-affected children were identified by medical chart review at one mid-west academic medical center. From a total eligible sample of 34 (based on diagnosis and/or phenotype), 24 households were targeted that adequately represented a range of ages, assigned gender, DSD diagnosis, and were located within one hour of the hospital to facilitate in-person focus groups. Six mothers and 5 fathers (n=11) of 6 DSD-affected children participated. An additional 6 parents of 5 children were interested in participating but could not be scheduled conveniently for any of the three parent focus groups. Diagnostic and clinical management characteristics of the participating parents’ children with DSD are summarized in Table 1.
Table 1.
Paticipating Parent | Child Age | Child Diagnosis | Child Phenotype | Child Gender | Child Genital Surgeries # | |
---|---|---|---|---|---|---|
Birth announcement | Current | |||||
Mother Father |
2 yo | Partial androgen insensitivity | small phallus bifurcated scrotum penoscrotal hypospadias | Girl | Boy | 1 |
Mother | 2 yo | Mixed gonadal dysgenesis (45,XO/46,XY) | small left testicle; absent right testicle | Delayed – ambiguous genitalia | Boy | 5 |
Mother Father |
6 yo | 21-hydroxylase congenital adrenal hyperplasia (21-OH CAH) | clitoromegaly | Girl; shortly thereafter, boy; then girl | Girl | 1 |
Mother Father |
11 mos | 21-OH CAH | clitoromegaly | Delayed –ambiguous genitalia | Girl | 1 |
Mother Father |
4 yo | 46, XY hypospadias (without molecular diagnosis) | penoscrotal hypospadias | Girl | Boy | 3 |
Mother Father |
5 yo | 21-OH CAH | clitoromegaly urogenital sinus | Girl (at 9mos, did a “gender test”) | Girl | (pending additional surgery) |
Interviews began with a primary question followed by several follow-up prompts (see Table 2). Focus groups were audiotaped and transcribed verbatim, with one exception. In that case, recording was not possible due to limitations of the facility; instead, responses were thoroughly documented via note-taking by one of the investigators (ALQ). Two groups of research staff independently performed a content analysis of the transcriptions and categorized the content into discrete areas of concern. Topics were categorized as either child- or parent/family-centered and grouped into domains. Sampling of content was judged complete when transcripts from later focus groups failed to generate new concerns (i.e., saturation of content was reached).
Table 2.
HRQoL Dimension | Primary and Exemplar Follow-up Questions |
---|---|
Physical Functioning | In what ways does your child's medical condition affect his or her activities? Follow-up question: How does your child's medical condition affect typical family routines? |
Symptoms/Treatment | Tell me about your experiences & what you found/find stressful about your child's initial diagnosis and their treatment Follow-up question: What symptoms, or aspects of the treatment, bother your child the most? |
Psychological/Social | How do you think that your child’s condition (appearance, medical condition, parental discomfort or anxiety) affects him or her emotionally? Behaviorally? Educationally? Socially? Follow-up question: Are you experiencing any problems with daycare/school/babysitters because of your child’s condition due to concerns about his or her physical appearance including genital status, physical functioning, or getting germs from other children? |
Other | Selected examples:
|
Questions are in form used for parents; these received minor modifications to make them suitable for use with healthcare providers and advocates.
Data are presented in terms of the frequency with which each stakeholder group mentioned a specific concern. To adjust for differences in sample size between groups and length of transcripts, percentages of the total responses from each group within child- and family-centered domains are presented (Tables 3 and 4). To analyze whether there were substantive differences in the frequency of concerns mentioned both within and across stakeholder groups, discrepancies of ≥10% are discussed. A decision rule identifying discrepancies of > 10% was adopted to maximize the information presented across stakeholders, while limiting the number of pair-wise comparisons (38 comparisons using > 5% rule vs. 7 comparisons for parents using the > 10% rule).
Table 3.
Percentage of Endorsement by Stakeholder Group | |||||
---|---|---|---|---|---|
Domains and most frequently endorsed topics | Urologist (n = 7) (%) | Endocrinologist (n = 10) (%) | Mental Health (n = 4) (%) | Advocate (n = 4) (%) | Parent (n = 11) (%) |
Physical functioning (7 topics)
|
52 | 35 | 48 | 20 | 22 |
Gender concerns/Body image (9 topics)
|
9 | 26 | 10 | 37 | 22 |
Social functioning (5 topics)
|
4 | 13 | 3 | 20 | 13 |
Emotional functioning (1 topic)
|
0 | 0 | 0 | 0 | 4 |
Medications and procedures (7 topics)
|
35 | 26 | 38 | 23 | 39 |
Total topics (frequency) | 23 | 23 | 29 | 30 | 23 |
Table 4.
Percentage of Endorsement by Stakeholder Group | |||||
---|---|---|---|---|---|
Domains and most frequently endorsed topics | Urologist (n = 7) (%) | Endocrinologist (n = 10) (%) | Mental Health (n = 4) (%) | Advocate (n = 4) (%) | Parent (n = 11) (%) |
Decision making (7 topics)
|
4 | 6 | 2 | 9 | 2% |
Role functioning & family activities (10 topics)
|
14 | 6 | 8 | 9 | 10% |
Anatomy & voiding (2 topics)
|
6 | 0 | 5 | 4 | 1 |
Gender concerns (8 topics)
|
10 | 12 | 10 | 4 | 2 |
Appearance (3 topics)
|
1 | 1 | 2 | 4 | 1% |
Social functioning (8 topics)
|
5 | 8 | 13 | 5 | 6 |
Emotional functioning (8 topics)
|
4 | 4 | 13 | 6 | 6 |
Future worries (9 topics)
|
17 | 17 | 13 | 12 | 14 |
Communication/information (12 topics)
|
9 | 17 | 12 | 23 | 15 |
Disclosure (6 topics)
|
4 | 12 | 8 | 5 | 5 |
Medical management (12 topics)
|
14 | 7 | 5 | 10 | 22 |
Diagnosis (12 topics)
|
12 | 10 | 10 | 8 | 17 |
Total topics (frequencies) | 112 | 72 | 61 | 136 | 162 |
Inter-rater agreement. Level of coding agreement, within each stakeholder group (e.g., urologist, parent), was calculated across all transcripts. Rates of agreement were calculated as a percentage of “matches” on content categorization. Level of agreement ranged from 63% to 72%, with a mean 66% agreement across informants.
The study was approved by the Institutional Review Board of the School of Medicine and Biomedical Sciences, University at Buffalo, Children and Youth Institutional Review Board, DB#936.
Results
Content analysis of the focus groups and interviews revealed a wide range of concerns raised by these stakeholders. To facilitate analysis, the issues were divided into those focused on patients (Child-Centered; e.g., difficulty voiding) and those focused on families (Family-Centered; e.g., stress of remembering medications). Although a variety of issues were mentioned for both children and families, a greater number and more diverse array of concerns were mentioned in the Family-Centered domain. Overall, 29 unique concerns were mentioned for children and 97 for parents/families (see Tables 3 and 4).
Child-Centered Domains (Table 3)
Health care providers (i.e., urologists, endocrinologists, mental health professionals) endorsed more concerns (35%–52%) regarding “Physical Functioning” than advocates (20%) and parents (22%). In contrast, advocates (37%), endocrinologists (26%) and parents (22%) focused more on “Gender Concerns and Body Image” than urologists (9%) and mental health professionals (10%). Further, urologists, mental health professionals, and parents endorsed more concerns about “Medications and Procedures” (range = 35%–39%) than advocates (23%); parents reported more concerns in this domain (range = 38%–39%) than endocrinologists (26%).
Parent/Family-Centered Domains (Table 4)
More concerns were mentioned that were coded as falling in the Family-Centered domain and these were spread over a wider range of domains and topics (Table 4); accordingly, the percentage of concerns falling within specific domains was smaller. Parents’ predominant concerns fell into the domains of “Diagnosis,” “Medical Management,” “Communication/Information,” and “Future Worries” (14–22%). In contrast, endocrinologists, mental health professionals, and advocates endorsed medical management concerns less often (5%–10%) than parents (22%). Endocrinologists and advocates emphasized “Communication/Information” (17% and 23%, respectively) and Future Worries (17% and 12%) issues; for both stakeholder groups, these were two most frequently mentioned areas of concern. Notably, endocrinologists reported more “Gender Concerns” (12%) than parents (2%).
DISCUSSION
Note: Based on reviewer suggestions, most of the 1st two paragraphes were deleted.
We found general agreement among health care providers about the major concerns faced by children with DSD and their families; however there were significant differences between stakeholder groups. All stakeholders were concerned that experiences such as repeated genital exams and painful medical procedures might exert negative effects on children, including self-consciousness about their condition. Limiting the number of these exams/interventions, determining when they are necessary, and utilizing strategies to reduce the potential negative psychological sequelae are important implications of these findings. Incorporating behavioral health clinicians (e.g., psychologists or child life specialists) who have expertise in preparing children for medical procedures (e.g., desensitization to needles and/or genital exams) could be very useful in the care of children with DSD. These providers can promote effective coping through medical play, preparation, and education.
The health care provider stakeholders focused more concern over physical functioning (especially urinary voiding) than did parents and advocates. This information is of particular importance to urologists who, in large part, look to parents’ expectations as an indication of whether surgery is warranted. Note: Much of this paragraph deleted based on reviewer suggestions.
Predominant for the parents were worries over the management of medications (e.g., giving medications at the appropriate time; stress of remembering). Although this issue was restricted, in our sample, to girls with classic congenital adrenal hyperplasia – a life-threatening condition requiring lifelong hormone replacement – this condition is the most common cause of DSD in persons with a 46, XX karyotype and represented 50 percent of the children of parents participating in this study. In contrast, concern over medications constituted a relatively small proportion of endocrinologists’ overall discussion (7%). Given the discrepancy in perceptions, it may be helpful for endocrinologists to provide parents with a written treatment plan that differentiates routine hormone replacement from stress dosing and to offer common strategies, such as cell phone alarms and visual reminders 15,16 to facilitate adherence to the treatment regimen. Education and ongoing support for dealing with the challenges of medication adherence have proven helpful.
For the advocates, concerns over communication/information dominated other topics categorized as Parent/Family-Centered (23% of 136 comments), although the other stakeholder groups also considered this a stressor (9–17%). It is possible that advocates were recalling an era of care for persons with DSD characterized by limited disclosure of diagnostic and other medical/surgical information to patients and, occasionally, even parents 17–19. The consensus statement on DSD 4 underscores the importance of transparent communication of diagnostic and procedural information with parents, along with developmentally-sensitive education of patients. Although the knowledge base regarding the etiology of DSD has expanded and communication practices may have improved, this is an area that continues to be challenging. As in other chronic conditions, a comprehensive understanding of the condition is a necessary prerequisite for shared decision-making and patient/family-centered care.
In general, more Parent/Family- than Child-Centered concerns were raised. Given that children in this age range could not be directly interviewed, we may not have adequately captured the child’s own perspective. It is also likely that children in this age group (less than 7 years) experience the DSD and its management as less of an issue than their parents. Their perceptions of the influence of their condition on daily life may change with age as there is a progressive developmental shift towards peers and social interactions outside the family. We are planning a study of affected school-age children to directly assess their issues and concerns.
The differences observed among stakeholders in this study have potentially important consequences for clinical care. As we move from an era of physician-driven to patient/family-centered care and shared decision-making, it will be important for DSD specialists to consider not only the viewpoints of patients (and, in the case of young children, their parents) but also the varying perspectives of health care providers involved in caring for these children 20. The current focus on systematically assessing patient-reported outcomes is one mechanism for achieving a greater understanding of patient and family views and preferences 7,8. The development of HRQoL measures for parents of young children with DSD would be ideal for systematically identifying parental concerns as they arise during the course of clinical management 21.
The diversity of perspectives of those involved in caring for newborns and young children with DSD highlights the need for strong channels of communication among members of the DSD healthcare team and between the team and family. Indeed, as different health professionals direct patient care priorities, it would behoove them to be aware of the opinions of other stakeholders. As noted in several recently published papers on the management of DSD 22–24, the goal is to develop tightly coordinated and integrated services that emphasize clear communication with the family, rather than simply offering services at the same location.
One limitation of this study is the somewhat wide age range (children were 11 mos-6 yrs). Our goal was to focus on young children, but recognize that even in this group there will be a range of issues that may be more prominently remembered at certain time points. For example, issues around surgery may much more be vivid for parents of children around a year of age and much less so for those parents whose children are older. For the most part, this limitation would apply primarily to the parent group.
This study is qualitative which, by its nature, employs in-depth interviews with small samples. Non-random sampling is guided by selection of participants most likely to yield insights into the phenomenon under investigation 14,25. Healthcare providers and advocates were selected for this study because of their depth of experience in managing the medical/surgical care of affected persons and, especially in the case of advocates, communicating/advocating on patients’ behalf. Of note, these participants were not randomly selected. Similarly, we interviewed 11 parents of six young children with DSD who were otherwise healthy and who represented a range of DSD diagnoses. Note that specific parental concerns may vary based on the heterogeneity of these conditions and their impact, but we aimed to include as diverse a sample as possible. Related primarily to the focus on the age range of 11 mos-6 yrs, only one affected patient was included (a member of the advocate group). We are in the process of conducting a multisite study involving a large sample of patients with DSD and their families using a newly developed HRQoL measure that focus on issues specific to, and shared by, young patients with DSD and their families 21. This larger study will allow us to test the generalizability of the parental concerns documented here and determine the degree to which distinct diagnoses (e.g., CAH) are associated with specific stressors and concerns.
CONCLUSION
We found that concerns related to the diagnosis and management of DSD varied according to stakeholder group: health care specialists, advocates, or parents. These results highlighted the importance of seeking the full range of informed perspectives, especially those of parents of young DSD-affected children. The primary role of an integrated, interdisciplinary team would be to assess all of these perspectives and provide care that is founded on a patient- and family-centered model.
Acknowledgments
This project was supported in part by Award # R21HD044398 and R01HD053637 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and by the Capital Region Medical Research Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health or the Capital Region Medical Research Foundation. The authors thank the healthcare providers, patient advocates, and parents who participated in the focus groups. We also thank Erica Eugster, MD for assistance in recruiting participating parents and the research staff who assisted in coding the transcripts, including Cheryl Twaragowski and Lolita Ontiveros.
Footnotes
Note: none of the authors are members of ESPE
References
- 1.Sanders C, Carter B, Goodacre L. Parents’ narratives about their experiences of their child's reconstructive genital surgeries for ambiguous genitalia. Journal of Clinical Nursing. 2008;17:3187–95. doi: 10.1111/j.1365-2702.2007.02006.x. [DOI] [PubMed] [Google Scholar]
- 2.Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Quality of Life Research. 1996;5:35–46. doi: 10.1007/BF00435967. [DOI] [PubMed] [Google Scholar]
- 3.Osaba D, Hsu M, Copley C, et al. Stated preferences of patients with cancer for health-related quality of life (HRQOL) domains during treatment. Quality of Life Research. 2005;15:273–83. doi: 10.1007/s11136-005-0580-5. [DOI] [PubMed] [Google Scholar]
- 4.Lee PA, Houk CP, Ahmed SF, Hughes IA in collaboration with the participants in the International Consensus Conference on Intersex. Consensus statement on management of intersex disorders. Pediatrics. 2006;118:e488–e500. doi: 10.1542/peds.2006-0738. [DOI] [PubMed] [Google Scholar]
- 5.Dayner JE, Lee PA, Houk CP. Medical treatment of intersex: Parental perspectives. The Journal of Urology. 2004;172:1762–5. doi: 10.1097/01.ju.0000138519.12573.3a. [DOI] [PubMed] [Google Scholar]
- 6.MacKenzie D, Huntington A, Gilmour JA. The experiences of people with an intersex condition: A journey from silence to voice. Journal of Clinical Nursing. 2009;18:1775–83. doi: 10.1111/j.1365-2702.2008.02710.x. [DOI] [PubMed] [Google Scholar]
- 7.Fayers P, Hays R, editors. Assessing quality of life in clinical trials. 2. New York: Oxford University Press; 2005. [Google Scholar]
- 8.Quittner AL, Cruz I, Modi AC, Marciel KK. Health-related quality of life instruments for adolescents with chronic diseases. In: O'Donohue WT, Tolle LW, editors. Behavioral approaches to chronic disease in adolescence. New York: Springer; 2009. pp. 311–27. [Google Scholar]
- 9.U S. Department of Health Human Services FDA Center for Drug Evaluation Research, U.S. Department of Health Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health Human Services FDA Center for Devices and Radiological Health. Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health and Quality of Life Outcomes. 2006;4:79. doi: 10.1186/1477-7525-4-79. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Palermo TM, Long AC, Lewandowski AS, Drotar D, Quittner AL, Walker LS. Evidence-based assessment of health-related quality of life and functional impairment in pediatric psychology. Journal of Pediatric Psychology. 2008;33:983–96. doi: 10.1093/jpepsy/jsn038. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Hays R. Generic versus disease-targeted instruments. In: Fayers P, Hays R, editors. Assessing quality of life in clinical trials. New York: Oxford University Press; 2005. pp. 3–8. [Google Scholar]
- 12.Birbeck GL, Kim S, Hays RD, Vickery BG. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia. 2002;43:535–8. doi: 10.1046/j.1528-1157.2002.32201.x. [DOI] [PubMed] [Google Scholar]
- 13.Quittner AL, Davis MA, Modi AC. Health-related quality of life in pediatric populations. In: Roberts MC, editor. Handbook of pediatric psychology. New York: Guilford Press; 2003. pp. 696–709. [Google Scholar]
- 14.Creswell JW. Qualitative inquiry & research design. Thousand Oaks, CA: Sage Publications; 2007. [Google Scholar]
- 15.Marciel KK, Saiman L, Quittell LM, Dawkins K, Quittner AL. Cell phone intervention to improve adherence: Cystic fibrosis care team, patient, and parent perspectives. Pediatric Pulmonology. 2010;45:157–64. doi: 10.1002/ppul.21164. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Quittner AL, Modi AC, Lemanek KL, Ievers-Landis CE, Rapoff MA. Evidence-based assessment of adherence to medical treatments in pediatric psychology. Journal of Pediatric Psychology. 2008;33:916–36. doi: 10.1093/jpepsy/jsm064. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Daaboul J, Frader J. Ethics and the management of the patient with intersex: A middle way. Journal of PediatricEndocrinology & Metabolism. 2001;14:1575–83. doi: 10.1515/jpem.2001.14.9.1575. [DOI] [PubMed] [Google Scholar]
- 18.Frader J, Alderson P, Asch A, et al. Health care professionals and intersex conditions. Archives of Pediatrics & Adolescent Medicine. 2004;158:426–8. doi: 10.1001/archpedi.158.5.426. [DOI] [PubMed] [Google Scholar]
- 19.Chase C. What is the agenda of the intersex patient advocacy movement? Endocrinologist. 2003;13:240–2. [Google Scholar]
- 20.Meyer-Bahlburg HFL. Treatment guidelines for children with disorders of sex development. Neuropsychiatrie de l'Enfance et de l'Adolescence. 2008;56:345–9. [Google Scholar]
- 21.Sandberg D, Gardner M, Kogan B, et al. Assessing health-related quality of life in disorders of sex development: Phase i - item generation. In: New M, Simpson J, editors. Hormonal and genetic basis of sexual differentiation disorders and hot topics in endocrinology: Proceedings of the 2nd world conference, advances in experimental medicine and biology. New York: Springer Science+Business Media; 2011. pp. 707pp. 143–6. [DOI] [PubMed] [Google Scholar]
- 22.Auchus R, Witchel S, Leight K, et al. Guidelines for the development of comprehensive care centers for congenital adrenal hyperplasia: Guidance fromthe cares foundation initiative. International Journal of Pediatric Endocrinology. 2010;2010 doi: 10.1155/2010/275213. 17 pages. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Douglas G, Axelrad M, Brandt M, et al. Consensus in guidelines for evaluation of DSD by the texas children's hospital multidisciplinary gender medicine team. International Journal of Pediatric Endocrinology. 2010;2010 doi: 10.1155/2010/919707. 17 pages. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Schaeffer T, Tryggestad J, Mallappa A, et al. An evidence-based model of multidisciplinary care for patients and families affected by classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Internaltional Journal of Pediatric Endocrinology. 2010;2010 doi: 10.1155/2010/692439. 13 pages. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Kazdin AE. Research design in clinical psychology. Boston: Allyn and Bacon; 2003. [Google Scholar]